Bionano Genomics director granted 9,149 stock options

Bionano Genomics director Kristiina Vuori, MD received a new stock option grant.

Rhea-AI Filing Summary

Bionano Genomics director Kristiina Vuori, MD received a new stock option grant. She was awarded options covering 9,149 shares of common stock at an exercise price of $1.19 per share. These options are held directly and represent compensation rather than an open-market purchase.

The options will vest in equal monthly installments over 12 months following the grant date and will in any case be fully vested by the company’s next annual stockholder meeting, so long as her continuous service continues through each vesting date. The award also fully vests upon a Change of Control under the company’s 2018 equity incentive plan, and expires on May 13, 2036 if not exercised.

Insider Trade Summary

Grant/Award: 9,149 shares

Grant/Award 1 txn

Insider Vuori Kristiina MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,149	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,149 contracts (Direct)

Footnotes (1)

1. F1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).

Key Figures

Option grant size: 9,149 shares Exercise price: $1.19 per share Shares underlying options: 9,149 shares +3 more

6 metrics

Option grant size 9,149 shares Stock Option (Right to Buy) awarded to director

Exercise price $1.19 per share Strike price for the 9,149-share option grant

Shares underlying options 9,149 shares Common stock underlying the granted options

Total options after grant 9,149 options Total derivative securities following this transaction

Vesting period 12 months Equal monthly vesting over 12 months after grant

Option expiration May 13, 2036 Expiration date of the stock option grant

Key Terms

Stock Option (Right to Buy), Continuous Service, Change of Control, 2018 equity incentive plan

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Continuous Service financial

"subject to the option holder's Continuous Service through each such vesting date"

Change of Control financial

"will vest in full upon a Change of Control as defined in the plan"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

2018 equity incentive plan financial

"as defined in the Company's 2018 equity incentive plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bionano Genomics (BNGO) disclose about Kristiina Vuori's new grant?

Bionano Genomics disclosed that director Kristiina Vuori, MD received a stock option grant for 9,149 shares of common stock at an exercise price of $1.19 per share, structured as equity compensation rather than an open-market share purchase.

How many Bionano Genomics (BNGO) shares are covered by Vuori's stock options?

The grant covers options on 9,149 shares of Bionano Genomics common stock. These options give her the right to buy that number of shares at $1.19 per share, subject to vesting and expiration terms defined in the company’s 2018 equity incentive plan.

What is the exercise price and expiration date of Vuori's BNGO stock options?

The options have an exercise price of $1.19 per share and an expiration date of May 13, 2036. If she does not exercise by that date, the options lapse and no longer provide the right to purchase Bionano Genomics common stock.

How do Kristiina Vuori's Bionano Genomics stock options vest?

The options vest in equal monthly installments over the 12 months following the grant date and will in any case be fully vested by the company’s next annual stockholder meeting, provided she maintains continuous service with Bionano Genomics through each monthly vesting date.

What happens to Vuori's BNGO options upon a Change of Control?

Upon a Change of Control, as defined in Bionano Genomics’ 2018 equity incentive plan, Vuori’s stock options vest in full immediately. This accelerates vesting, allowing her to exercise the entire 9,149-share option grant regardless of the normal monthly vesting schedule.

Is Vuori's Form 4 transaction a market purchase of BNGO shares?

No. The Form 4 reports a compensation-related stock option grant, coded as a grant or award acquisition, not an open-market share purchase. She received options to buy 9,149 shares at $1.19, which may be exercised later once vested and before expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 06:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vuori Kristiina MD

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.19	05/14/2026		A		9,149		(1)	05/13/2036	Common Stock	9,149	$0	9,149	D

Explanation of Responses:

1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).

	/s/ Jonathan V. Dixon, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)